Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

Abstract excerpt

PURPOSE: Mutations in the ATM gene are common in multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement of ATM loss of function (LOF) as a predictive biomarker of response is urgently needed. EXPERIMENTAL DESIGN: We present the first disclosure and preclinical development of a novel, selective ATR inhibitor, ART0380, and test its antitumor...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Autoimmune Neurological Disorders and Treatments
• Share to DNA Repair Mechanisms
• Share to Genetics and Neurodevelopmental Disorders